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A 50-year-old woman was diagnosed with acute myeloid leukemia (AML). She has history of thrombocytopenia for
25 years and a significant family history of thrombocytopenia, affecting her mother, siblings and their children, as well as
her own children. Both her mother and maternal aunt died from myelodysplastic syndrome (MDS). Additional genetic
analysis was performed and identified two heterozygous missence mutations in the second zinc finger domain of GATA2
gene (p.Thr358Lys, and p.Leu359Val), occurring in cis on the same allele. Given the patient’s family history and clinical
manifestation, this was interpreted as an acute myeloid leukemia with heritable GATA2 mutations associated with familial
AML-MDS. Germline GATA2 mutations are involved in a group of complex syndromes with overlapping clinical features
of immune deficiency, lymphedema and propensity to acute myeloid leukemia or myelodysplastic syndrome (AML-MDS).
Here we reported a case of familial AML-MDS with two novel GATA2 mutations. This case illustrates the importance of
recognizing the clinical features for this rare category of AML-MDS and performing the appropriate molecular testing. The
diagnosis of heritable gene mutations associated familial AML-MDS has significant clinical implication for the patients and
affected families. Clinical trials are available to further investigate the role of allogeneic hematopoietic stem cell transplant
in managing these patients.
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MDS and AML are mostly sporadic hematopoetic malig-
nancies typically affecting older patients. Familial occur-
rence of MDS or AML is rare, and most of these cases
arise in the setting of genetic syndromes associated with
increased risks of developing AML or MDS, including sev-
eral inherited bone marrow failure syndrome, such as
Diamond-Blackfan anemia, severe congenital neutropenia,
Shwachman-Diamond syndrome, and dyskeratosis con-
genital. Rare familial cases of MDS and AML have been
reported in families without congenital syndromes who
carry germ line predisposing mutations. Examination of
families with MDS and AML has led to the detection of
several inherited mutations in RUNX1 or CEBPA, and* Correspondence: j-gao@northwestern.edu
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unless otherwise stated.more recently GATA2. Here we reported a case of familial
MDS-AML with two novel GATA2 mutations.Case report
A 50-year-old Caucasian woman with a 25 year history of
thrombocytopenia presented to the emergency depart-
ment with worsening cough and high fever and was diag-
nosed with bilateral multilobar Legionella pneumonia. Her
clinical condition deteriorated rapidly into multiorgan fail-
ure, requiring pressors, hemodialysis, and artificial ventila-
tion. She was noted to have circulating blasts in the
peripheral blood.
She had a significant family history of thrombocytopenia,
affecting her mother, siblings and their children, as well as
her own children. Both her mother and maternal aunt died
from MDS.
Her peripheral blood revealed normochromic normocytic
anemia with hemoglobin of 9.5 g/dL, thrombocytopenia
(55,000/uL), white blood cells of 8700/μL, including 25% of. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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revealed scattered blasts with high nuclear to cytoplasmic
ratio, some with cytoplasmic granules. Occasional dysplas-
tic neutrophils with hyposegmented nuclei were also noted.
Some of the platelets were large and irregular (Figure 1A).
Bone marrow aspirate smears were diluted by peripheral
blood, but there were blasts with fine chromatin, round nu-
clei and scant cytoplasm (Figure 1B). The particle clot and
core biopsy sections showed markedly hypercelluar mar-
row with increased blasts (Figure 1C, D). Flow cytometric
immunophenotyping performed on the bone marrow as-
pirate revealed a myeloid blast population that was partial
CD34+, CD117+, with dim expression of myeloperoxidase,
CD13 and CD33, and aberrant expression of CD7. The
flow cytometric results support the diagnosis of acute
myeloid leukemia. Cytogenetic analysis performed on
fresh bone marrow aspirate revealed 46,XX,del(7)(q22q36)
[20] (Figure 2A). Based on the morphologic and cytogen-
etic findings, the patient was diagnosed with acute myeloid
leukemia with myelodysplasia related changes. Molecular
tests for FLT3 ITD, FLT3 D835 and NPM1 were performed
on DNA extracted from fresh bone marrow aspirates using
an automated nucleic extraction instrument QIAsymphony
followed by previously described methodology [1,2]. CEBPA
and KIT mutational analyses were sent to Blood Center of
Wisconsin and Mayo Medical Laboratory respectively.Figure 1 Morphological findings of familial AML-MDS with inherited G
number of blasts, occasional dysplastic neutrophils with hyposegmented n
(B) Bone marrow aspirate smears contain occasional blasts with fine chrom
and (D) The bone marrow core biopsy sections showed a markedly hyperc
(C: Hematoxylin and eosin, ×200, D: Hematoxylin and eosin, ×600).These tests did not identify mutations involving FLT3 ITD,
FLT3 D835, NPM1, CEBPA, and KIT genes. Given her sig-
nificant family history of thrombocytopenia and MDS,
there was a concern for a heritable mutation as a predispos-
ition gene for familial MDS-AML. Additional genetic ana-
lysis of RUNX1 as previously described did not reveal any
mutations [3]. Sanger sequencing was performed to screen
the known mutation of GATA2 and identified two hetero-
zygous missence mutations in the second zinc finger
domain of GATA2 gene (p.Thr358Lys, and p.Leu359Val)
(Figure 2B, Table 1). The two mutations occur in cis on the
same allele, as determined by subcloning and sequencing
individual clones. Given the patient’s family history and
clinical manifestation, this was interpreted as an acute mye-
loid leukemia with heritable GATA2 mutations associated
with familial AML-MDS. Patient required multiple cycles
of chemotherapy to achieve a remission and eventually
underwent a double umbilical cord hematopoietic stem cell
transplant (HSCT) with reduced intensity conditioning.
Unfortunately, she died 6 months later due the transplant-
related complications while in complete morphologic, cyto-
genetic, and molecular remission, demonstrating 100% sin-
gle cord donor chimerism. Although it was recommended
to confirm the germ line nature of the GATA2 mutation by
submitting additional material such as a skin biopsy or a
buccal swab for germline GATA2 testing, it was notATA2 mutations. (A) Peripheral blood smear revealed increased
uclei and platelets with abnormal morphology (Wright-Giemsa, ×400).
atin, round nuclei and scant cytoplasm (Wright-Giemsa, ×1000). (C)
elluar bone marrow with significantly increased numbers of blasts








Figure 2 Cytogenetic and molecular findings of familial AML-MDS with inherited GATA2 mutations. (A) Cytogenetic analysis performed
on fresh bone marrow aspirate revealed all 20 cells with a deletion of long arm of chromosome 7, i.e. 46,XX,del(7)(q22q36)[20]. (B) To screen
GATA2 for known mutations, PCR products were amplified by either Qiagen Taq or by Roche GC rich PCR kit using primers listed in table below.
PCR products were Sanger sequencing using the same primers with Big Dye chemistry (ABI) on a 3730xl DNA Analyzer (ABI). Bidirectional Sanger
sequencing revealed 2 heterozygous mutations in 2nd zinc finger domain of GATA2 gene, p. Thr358Lys (c.1074 C > A) and p.Leu359Val (c.1076 T > G).
To differentiate whether the mutations were cis or trans, PCR products were cloned into a pCI vector (Promega) and 8 clones were sequenced. Of the
8 clones, 3 failed to produce sequence information, 2 contained both wild type alleles and 3 contained both mutant alleles.
Table 1 Primers used in GATA2 sequencing
Exon Forward primer Reverse primer PCR size
e1 tcctttcgttttgagccttg ttttcagcagctcgattcct 552
e2 ctggttctgggagtcgtgat catcttcatgctctccgtca 542
“” ggaggcccactctctgtgta cctctcccaagtcacagctc 548
e3 agaccctctcgtccctcttc agacgaccccaactgacatc 464
e4 cttgcaatcccgttgattct agccaagctggatattgtgg 466
e5 ctatgaaggtcgggcacaat gtcctcgacgtccatctgtt 457
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ent chronic infection and respiratory failure. Other family
members declined testing for GATA2 mutations.
Discussion
GATA2 is a transcription factor crucial for hematopoietic
differentiation and lymphatic formation. The biologic func-
tion of GATA2 in hematopoiesis is diverse through interac-
tions with various transcriptional factors and cofactors.
GATA2 plays an essential role in maintaining the prolifera-
tion and survival of early hematopoietic cells, as well as
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lineages [4,5]. Expression of GATA2 is significantly higher
in AML compared to normal bone marrow, and is an ad-
verse indicator of prognosis [6,7]. Mutations involving
GATA2 coding sequence are not common in sporadic
AML cases, and are frequently associated with a more spe-
cific subgroup of AML with normal cytogenetics and bial-
lelic CEBPA mutations. In these cases, somatic mutation of
GATA2 is likely a secondary event in the leukemogenesis
[6,8-10]. However, germline GATA2 mutations have a very
different oncogenic role. Germline GATA2 mutations are
involved in a group of complex syndromes with overlap-
ping clinical features, including a rare genetic disorder
called MonoMAC, Emberger syndrome and familial AML
following MDS. These diverse syndromes may reflect dif-
ferent clinical manifestations of the common underlying
defect of GATA2 deficiency. MonoMac is a complex con-
genital immunodeficiency characterized by persistent and
profound peripheral monocytopenia, B- and NK-cell lym-
phocytopenia, near absence of dendritic cells and increased
susceptibility to mycobacterium or papilloma virus infec-
tions [11-13]. Emberger syndrome is characterized by pri-
mary lymphedema inherited in an autosomal dominant
pattern [14,15]. Both syndromes are associated with a pre-
disposition to acute myeloid leukemia and myelodysplastic
syndrome. GATA2 has recently been recognized as a
MDS-AML predisposition gene, in addition to the previ-
ously reported RUNX1 and CEBPA. Since the first report
of 4 families of heritable GATA2 mutations associated with
familial AML-MDS by Hahn et al. in 2011, [10] there have
been more than a dozen pedigrees reported in the litera-
ture (Table 2). Studies of these families provide significant
insights on the genetic and clinical features of this rare
form of AML-MDS.
Patients with familial AML-MDS are younger at presen-
tation than individuals with sporadic disease. Most of the
families manifest an unusual family history of more than
one first-degree relative with AML-MDS, consistent with
a pattern of autosomal dominant inheritance. But there is
clearly heterogeneity in the clinical features from the cases
reported [10,17]. The patients may or may not have prece-
dent hematologic abnormalities, and the onset age of
AML-MDS in affected family members are variable. Cases
described also demonstrate a spectrum with differentTable 2 Reported pedigrees of germline GATA2 deficiency ass
Authors Pedigrees Mutation
Hahn et al. [10] 4 pedigrees p.Thr354Met, p.Thr355del
Bodor et al. [16] 1 pedigree p.Thr354Met
Holm et al. [17] 4 pedigrees p.Leu105ProfsX15, p.Pro41Ala, p.Arg39
Pasquet et al. [18] 7 pedigrees p.Arg396Gln, p.Arg204X, p.Glu224X, p
p.Met388Val, and a 61 kb deletion of
Kazenwadel et al. [19] 2 pedigrees p.Thr354Met, p.Met1del290morphologic subtypes and variable cytogenetic abnormal-
ities, including most frequently monosomy 7, but also tri-
somy 8, and trisomy 21 [10].
The mutations associated with GATA2 also demonstrate
marked genetic heterogeneity [17]. The GATA2 protein
contains a transactivation domain in the N-terminus and
two highly conserved zinc finger (ZF) domains. Mutations
previously described are highly heterogeneous ranging
from single base substitutions, insertions and deletions,
and are present throughout the gene. There are two major
classes of mutations involving GATA2 reported [20]. Mul-
tiple studies described N-terminal frameshift mutations
cause premature terminations and result in a nonfunc-
tional protein lacking most of the C-terminal [21]. The
mutations in C-terminal zinc finger domains are predicted
to cause significant structural alterations critical for inter-
action with DNA, other transcription factors and cofac-
tors, causing more variable phenotypic consequences [17].
The mutations reported from affected families are variable
and present throughout the GATA2 gene (Table 2). The
majority of these mutations are missence mutation, with
the p.Thr354Met mutation being the most frequently mu-
tated in the reported families [10,16,17,19].
The p.Thr358Lys and p.Leu359Val reported in this
case have not been seen as a germline event in familial
AML/MDS in the literature. The p.Thr358Lys mutation
is listed on the NHLBI Exome Variant Server (http://evs.
gs.washington.edu/EVS/) at a frequency of 1/4000 indi-
viduals without available history, but may include some
with the potential to develop MDS. It is not a known
genetic variant in the single nucleotide polymorphism
site in the Single Nucleotide Polymorphism Database
(dbSNP). The p.Leu359Val has been exclusively identified
in myeloid transformation of chronic myeloid leukemia
[22]. Zhang et al. reported a p.Leu359Val in 8 of 85 cases of
CML in blast crisis and associated with myelomonoblastic
features [22]. Further studies demonstrated p.Leu359Val
has a gain of function effect with increased transactivation
activity of GATA2 but also enhanced its inhibitory effects
on the activity of PU.1, a major transcription factor for
myeloid cell differentiation, via aberrant protein–protein
interaction [22]. Although neither mutation has not been
reported in familial MDS-AML in the literature, nearby res-




6Glu, p.Thr354Met Familial AML-MDS, lymphedema, skin cancer
.Arg330X, p.Ala372Thr,
the GATA2 locus
Chronic neutropenia and evolution to AML-MDS
Familial MDS, MonoMac
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line mutations. These two mutations come from the same
parent as both occur on the same allele, but it is unclear
whether one of them is sufficient to cause the disease
phenotype.
GATA2 is probably an important predisposing muta-
tion but secondary genetic events are required for the
development of overt malignant disease. Acquiring other
genetic abnormalities may also affect the phenotype in
addition to the GATA2 mutation status. The secondary
genetic events in patients with heritable GATA2 muta-
tions associated with familial AML-MDS are still mostly
unknown, but several cases have been reported in which
acquired ASXL1 mutations are common in patients with
inherited GATA2 mutations. West et al. reported som-
atic, heterozygous ASXL1 mutations were identified in
14 of 48 (29%) patients with inherited GATA2 deficiency
and that correlated with myeloid transformation [23].
Partial or complete loss of chromosome 7 has been re-
ported as a common cytogenetic finding in multiple ped-
igrees with familial AML-MDS [24,25]. Chromosome 7
abnormalities are not inherited but likely represent a re-
curring secondary event in leukemogenesis and are fre-
quently linked to the development of AML-MDS.
Heritable GATA2 mutations associated with familial
myelodysplastic syndrome and acute myeloid leukemia
have only been described recently. There is no clear cor-
relation between the genotype and clinical outcome. Based
on limited cases reported in the literature, the affected in-
dividuals usually have a poor outcome unless successfully
transplanted [10,16]. A recent study reported six patients
who underwent allogeneic stem cell transplant for GATA2
deficiency had excellent outcomes except one who died
from infection [26]. Other anecdotal reports implied a less
ideal outcome [16]. It is likely other secondary genetic
event such as ASXL mutation and loss of chromosome 7
confer a poorer prognosis. Due to the rarity of affected
pedigrees, current clinical management and guidelines for
risk stratification and treatment are mostly based on ex-
pert opinion. However, there are clinical trials available
to elucidate the risk stratification and determine those
who might benefit from early intervention such as allo-
geneic bone marrow transplantation (ClinicalTrials.gov:
NCT01861106). Another important feature often compli-
cating the clinical course of patients with AML is infec-
tion, particularly intracellular organisms such as atypical
mycobacteria and viruses, as a result of underlying im-
munodeficiency due to cytopenias from AML-MDS and/
or chemotherapy. Serious infections are often the causes
of death, as seen in our patient.
It is import to identify familial cases of AML-MDS
and test the heritable mutations. A complete clinical and
family history is a clue to recognizing patients with an
inherited predisposition to myeloid neoplasm. Germlinetesting should be considered in a family with more than
one close relatives affected by AML-MDS or in patients
with early onset disease. A recent study based on large
population based registry data did not show that relatives
of patients with AML-MDS are at increased risk of
hematologic tumor, but there is a significant increased risk
of AML-MDS and other myeloid malignancies among first
degree relatives of patients diagnosed at younger than age
21 years [27]. This suggests that young age at the onset of
disease is probably the most useful indicator to look for
inherited factors in developing AML-MDS. Germline test-
ing should be performed in specimens containing only the
nonleukemic cells such as skin fibroblasts. Buccal swab or
saliva samples are acceptable; though these may contain
lymphocytes derived from hematopoietic stem cells. Given
the genetic heterogeneity in cases of germline GATA2 mu-
tation, sequencing of the entire coding region of GATA2 is
needed. With the anticipated rapid incorporation of next-
generation sequencing into clinical practice, testing genes
involved in inherited predisposition syndromes is becom-
ing increasingly available.
The detection of an underlying germ line mutation has
significant implications for clinical practice. Due to the poor
outcomes in the reported AML cases with GATA2 muta-
tions, aggressive and early intervention such as allogeneic
stem cell transplant should be considered. Family members
with identified germline mutations should be avoided as
stem cell donors. Although there is no direct data, family
members under consideration for being HSCT donors
should be tested to exclude mutations in the same predis-
position gene, due to the theoretical risk of developing
AML in the future from the graft with the same mutation.
Genetic counselling should be offered to the family mem-
bers, as germ line testing for these types of mutations has
ethical and psychological implications for those being tested
and their families. We would recommend mutation carriers
in the family to have CBC and a baseline bone marrow bi-
opsy to evaluate for occult myeloid neoplasm. Close clinical
follow up for affected family members is particularly im-
portant. For affected mutation carriers without morpho-
logic evidence of myeloid neoplasm , whether and when to
consider the HSCT is not known. Identification of prognos-
tic markers which may help select patients at high risk of
developing AML-MDS will be particularly helpful.
Conclusion
In addition to RUNX1 and CEBPA, GATA2 gene mutations
have only been recently reported involved in familial AML-
MDS. Here we reported two novel GATA2 mutations oc-
curring in cis on the same allele associated with a case of
familial AML-MDS. Heritable gene mutations as a predis-
position gene to AML-MDS are likely under recognized,
but have significant implication in managing the patients
and the affected families. It is important to recognize this
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seek appropriate laboratory testing when there is a clinical
concern. With the rapid availability of genetic testing, par-
ticularly in the era of next generation sequencing, accu-
mulating cases will provide insights to the molecular
events in leukemogenesis, and clinical trials aimed at iden-
tifying the appropriate treatment for specific molecular
subsets of AML will enhance our understanding of these
heterogeneous diseases and may benefit patients and their
families.
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